News Release

 

Back
 

AmerisourceBergen Reports Record Revenue and Record Diluted Earnings Per Share of $0.82 for the March Quarter

04/23/08

Company Terminates PMSI Sale Process

VALLEY FORGE, Pa.--(BUSINESS WIRE)--April 23, 2008--AmerisourceBergen Corporation (NYSE:ABC) today reported that in its fiscal year 2008 second quarter ended March 31, 2008, diluted earnings per share were a record $0.82, up 21 percent, and total revenue increased 8 percent to $17.8 billion, also a record.

AmerisourceBergen also announced that it has terminated the sale process for PMSI, its market-leading workers' compensation business, and is turning its attention to profit improvement initiatives to increase PMSI's performance. In discontinuing the sale process, the Company said that the final bids did not reflect the fair value of the business.

    Fiscal Second Quarter Highlights

    --  Record total revenue of $17.8 billion, up 8 percent.

    --  Record diluted earnings per share of $0.82, a 21 percent
        increase.

    --  Pharmaceutical Distribution operating margin (based on total
        revenue) of 1.34 percent, up 9 basis points.

    --  Cash flow from operations of $193 million.

    Fiscal First Six Months Highlights

    --  Record total revenue of $35.2 billion, up 6 percent.

    --  Record diluted earnings per share of $1.48, a 14 percent
        increase.

    --  Pharmaceutical Distribution operating margin (based on total
        revenue) of 1.23 percent, up 2 basis points.

    --  Cash flow from operations of $92 million.

    --  $395 million in share repurchases.

"Our record-setting March quarter results were driven by outstanding performance in our core distribution businesses due to excellent revenue growth, solid expense management, strong price appreciation and increased generic contributions," said R. David Yost, AmerisourceBergen's President and Chief Executive Officer. "This record performance was achieved despite the weaker performance in our Other Segment. Our working capital management remains excellent, and our balance sheet continues to be strong."

Commenting on the terminated sale process for PMSI, Yost said, "Because the final bids did not reflect the turnaround value of the business, which we expect to capture, we will focus on significantly improving the business and delivering that value to shareholders. We expect PMSI to improve in the second half of this fiscal year and deliver significant improvement in fiscal year 2009. In the future, we believe this business can be a strong, long-term contributor to shareholder value as part of AmerisourceBergen."

    Consolidated Results

    --  The Company will now report revenue expectations and calculate
        gross, expense and operating margins based on total revenue
        instead of operating revenue. Due to a recently completed new
        contract with an existing large institutional customer, a
        majority of that customer's bulk delivery business is now
        being serviced on an operating basis. As a result, the
        remaining annualized bulk revenue of approximately $1.8
        billion is not significant relative to total revenue. The
        Company will continue to break out both bulk deliveries and
        operating revenue in its financial tables.

    --  Total revenue was $17.8 billion in the second quarter of
        fiscal 2008 compared to $16.5 billion for the same period last
        year, an 8 percent increase. The increase was driven by a 9
        percent increase in the Pharmaceutical Distribution Segment,
        which was slightly offset by a decrease in total revenue in
        the Other Segment.

    --  Consolidated operating income in the fiscal 2008 second
        quarter increased 7 percent to $236.7 million from $220.9
        million in the previous fiscal year's second quarter, due to
        the 16 percent increase in operating income in the
        Pharmaceutical Distribution Segment, which was partially
        offset by a decline in the Other Segment. Special charges,
        primarily for the expense of the PMSI sale process, in the
        fiscal year 2008's second quarter had a $1.4 million negative
        impact on consolidated operating income. In the previous
        fiscal year's second quarter, special items had a net positive
        impact of $1.6 million.

    --  The effective tax rate for the second quarter of fiscal 2008
        was 38.9 percent, compared to 38.5 percent in the previous
        fiscal year's second quarter. The Company expects its
        annualized effective tax rate to be slightly above 38 percent
        for fiscal year 2008.

    --  Diluted earnings per share were up 21 percent to $0.82 in the
        second quarter of fiscal 2008 compared to $0.68 in the
        previous fiscal year's second quarter.

    --  In the fiscal 2007 second quarter, the PharMerica Long-Term
        Care business, spun-off in July 2007, benefited that quarter
        by $0.03 per diluted share. Excluding the impact of Long-Term
        Care in fiscal 2007, AmerisourceBergen's diluted earnings per
        share in the second quarter of fiscal year 2008 would have
        increased 26 percent.

    --  Average diluted shares outstanding for the second quarter of
        fiscal year 2008 were 163.3 million, down nearly 29 million
        shares from the previous fiscal year's second quarter due to
        share repurchases, net of option exercises.

    --  In the first six months of fiscal 2008, total revenue was
        $35.2 billion, a 6 percent increase over the $33.2 billion in
        total revenue in the previous fiscal year's first six months,
        and consolidated operating income was $431.7 million and
        $429.8 million in the first six months of fiscal 2008 and
        2007, respectively. For the first six months of fiscal 2008
        diluted earnings per share were $1.48 compared to $1.30 for
        the same period of the previous fiscal year, a 14 percent
        increase. In the first six months of fiscal 2007, diluted
        earnings per share were reduced by $0.03 due to the net impact
        of special items. In the same six-month period, the PharMerica
        Long-Term Care business added $0.06 to diluted earnings per
        share.

AmerisourceBergen consists of the following two reportable segments: Pharmaceutical Distribution (which includes the operations of AmerisourceBergen Drug Corporation, Specialty Group, Packaging Group and Bellco Health) and Other (which includes PharMerica Long-Term Care, through July 31, 2007, and PMSI). Intersegment sales of $14.9 million in the second quarter of fiscal 2008 from AmerisourceBergen Drug Corporation to PMSI, which are included in the Pharmaceutical Distribution Segment total revenue, are eliminated for consolidated reporting purposes.

    Pharmaceutical Distribution Segment Results

    --  Total revenue of $17.8 billion in the second quarter of fiscal
        2008 was up 9 percent compared to the same quarter in the
        previous fiscal year, due to an 8 percent increase in
        AmerisourceBergen Drug Corporation revenue, primarily from its
        institutional customers, and a 3 percent contribution from
        Bellco Health, which was acquired at the beginning of the
        fiscal year. Specialty Group total revenue was essentially
        flat, because of the expected impact from lower anemia drug
        sales and lost sales from the acquisition of a large Specialty
        Group customer by a competitor in November 2007.

    --  Gross profit as a percentage of total revenue increased 5
        basis points to 3.03 percent in the fiscal 2008 second quarter
        over the same period in the previous year driven by strong
        price appreciation in branded pharmaceuticals and increased
        contribution from generic drugs. The LIFO charge in the fiscal
        2008 second quarter was $9.6 million compared with a $1.6
        million charge in the previous year's second quarter,
        reflecting the branded price increases.

    --  Operating expenses as a percentage of total revenue in the
        fiscal second quarter of 2008 were 1.69 percent down 4 basis
        points from the same period in the previous fiscal year, due
        to lower operating expenses in Drug Corporation despite an 8
        percent increase in revenue.

    --  Operating income increased a robust 16 percent in the fiscal
        2008 second quarter compared with the previous year's second
        quarter due to excellent revenue growth, improved gross profit
        and solid expense management. As a percentage of total
        revenue, the operating margin in the fiscal 2008 second
        quarter was 1.34 percent, a 9 basis point increase over the
        same period in the previous fiscal year.

    Other Segment Results

    --  In the fiscal 2008 second quarter, PMSI contributed $105.4
        million in revenue and $783,000 of operating income compared
        to $114.6 million and $8.6 million, respectively, in the
        previous fiscal year's second quarter. The decline in
        operating income in the fiscal 2008 second quarter was due to
        customer losses, reductions in reimbursement and a significant
        increase in operating expenses related to ongoing information
        technology infrastructure and customer-facing projects. In the
        second quarter of 2007, the segment also included PharMerica
        Long-Term Care, which contributed revenue of $316.8 million
        and operating income of $6.8 million.

    --  While the Company expects improvement in PMSI's performance in
        the second half of fiscal 2008 and substantial improvement in
        fiscal 2009, operating margins for PMSI are now expected to be
        in the 2 percent to 3 percent range for fiscal year 2008, down
        from the previous expectations of 5 percent to 6 percent.

    Fiscal Year 2008 Expectations

"Though remaining within our original range, we are narrowing our expectations for fiscal year 2008 diluted earnings per share to a range of $2.77 to $2.87 from the previous range of $2.77 to $2.95, due primarily to the expected weaker performance of PMSI, as well as the impact from lower sales of anemia drugs in the Specialty Group and the slowing growth of the overall pharmaceutical market," said Yost. "This diluted earnings per share range represents an increase of about 13 percent to 17 percent over the $2.46 per share from continuing operations for fiscal year 2007, which continues to exclude the $0.09 benefit from special items and the $0.08 contribution from PharMerica Long-Term Care in fiscal year 2007.

"We are increasing our expectations for the repurchase of our common shares in fiscal year 2008. In the first half of fiscal 2008, we repurchased $395 million of our shares and now expect to use a substantial amount of the $302 million remaining in our current share repurchase authorization during the remainder of this fiscal year. As a result, we anticipate exceeding our previous expectation of repurchasing $400 million to $500 million of our shares in fiscal year 2008. We continue to expect free cash flow for fiscal year 2008 in the range of $450 million to $525 million, which includes capital expenditures in the $125 million range.

"Despite the change from operating revenue to total revenue guidance, we are retaining our key revenue and margin assumptions supporting our diluted earnings per share expectations in fiscal year 2008: Total revenue growth assumptions remain in the range of 7 percent to 9 percent, primarily due to the expected growth of our largest institutional customers; and we continue to expect operating margin expansion in the Pharmaceutical Distribution Segment will be in the low single-digit basis points range."

Fiscal Year 2009 Preview

Looking ahead to fiscal year 2009, Yost commented, "We have yet to start our detailed planning process for fiscal year 2009. However, in light of recently reduced pharmaceutical market growth predictions, I want to provide some perspective on our next fiscal year. If pharmaceutical market growth is in the 2 percent to 3 percent range, we see a clear path to low double-digit diluted earnings per share growth in fiscal year 2009 through operating margin expansion and strong cash generation. As in the past, we expect to announce our diluted earnings per share expectations for fiscal year 2009 when we release our fiscal 2008 results, currently scheduled for October 30, 2008."

Conference Call

The Company will host a conference call to discuss its results at 11:00 a.m. Eastern Time on April 23, 2008. Participating in the conference call will be: R. David Yost, President and Chief Executive Officer and Michael D. DiCandilo, Executive Vice President and Chief Financial Officer.

To access the live conference call via telephone:

    Dial in: (612) 332-0430, no access code required.

To access the live webcast:

Go to the Quarterly Webcasts section on the Investor Relations page at http://www.amerisourcebergen.com.

A replay of the telephone call and webcast will be available from 1:00 p.m. April 23, 2008 until 11:59 p.m. April 30, 2008. The Webcast replay will be available for 30 days.

To access the replay via telephone:

Dial in: (800) 475-6701 from within the U.S., access code: 917886
         (320) 365-3844 from outside the U.S., access code: 917886

To access the archived webcast:

Go to the Quarterly Webcasts section on the Investor Relations page at http://www.amerisourcebergen.com.

About AmerisourceBergen

AmerisourceBergen is one of the world's largest pharmaceutical services companies serving the United States, Canada and selected global markets. Servicing both pharmaceutical manufacturers and healthcare providers in the pharmaceutical supply channel, the Company provides drug distribution and related services designed to reduce costs and improve patient outcomes. AmerisourceBergen's service solutions range from pharmacy automation and pharmaceutical packaging to reimbursement and pharmaceutical consulting services. With more than $66 billion in annual revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs approximately 11,200 people. AmerisourceBergen is ranked #28 on the Fortune 500 list. For more information, go to www.amerisourcebergen.com.

Forward-Looking Statements

This news release may contain certain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in any forward-looking statements: changes in pharmaceutical market growth rates; competitive pressures; the loss of one or more key customer or supplier relationships; changes in customer mix; customer or supplier defaults or insolvencies; changes in pharmaceutical manufacturers' pricing and distribution policies or practices; adverse resolution of any contract or other disputes with customers (including departments and agencies of the U.S. Government) or suppliers; regulatory changes (including increased government regulation of the pharmaceutical supply channel); government enforcement initiatives (including (i) the imposition of increased obligations upon pharmaceutical distributors to detect and prevent suspicious orders of controlled substances (ii) the commencement of further administrative actions by the U. S. Drug Enforcement Administration seeking to suspend or revoke the license of any of the Company's distribution facilities to distribute controlled substances, (iii) the commencement of any enforcement actions by any U.S. Attorney alleging violation of laws and regulations regarding diversion of controlled substances and suspicious order monitoring), or (iv) the commencement of any administrative actions by the board of pharmacy of any state seeking to suspend, revoke or otherwise restrict the ability of any of the Company's distribution facilities or businesses to distribute or dispense pharmaceuticals in such state; changes in U.S. government policies (including reimbursement changes arising from federal legislation, including the Medicare Modernization Act and the Deficit Reduction Act of 2005); changes in regulatory or clinical medical guidelines, reimbursement practices and/or labeling for the pharmaceuticals we distribute, including erythropoiesis-stimulating agents (ESAs) used to treat anemia patients; price inflation in branded pharmaceuticals and price deflation in generics; fluctuations in market interest rates; operational or control issues arising from the Company's outsourcing of information technology activities; success of integration, restructuring or systems initiatives; fluctuations in the U.S. dollar - Canadian dollar exchange rate and other foreign exchange rates; economic, business, competitive and/or regulatory developments in Canada, the United Kingdom and elsewhere outside of the United States; acquisition of businesses that do not perform as we expect or that are difficult for us to integrate or control; any disruption to or other adverse effects upon the PMSI workers' compensation business caused by the Company's decision to terminate its previously-announced sale process for PMSI; further declines in PMSI's performance due to further customer losses, reimbursement reductions and/or competitive pressures; the inability of the Company to successfully undertake profit improvement initiatives and other measures to improve PMSI's performance; the inability of the Company to successfully complete any other transaction that the Company may wish to pursue from time to time; changes in tax legislation or adverse resolution of challenges to our tax positions; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the business of the Company generally. Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors) in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2007 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act of 1934.


                    AMERISOURCEBERGEN CORPORATION
                          FINANCIAL SUMMARY
                (In thousands, except per share data)
                             (unaudited)


                         Three                Three
                      Months Ended  % of   Months Ended  % of
                       March 31,    Total   March 31,    Total    %
                          2008     Revenue     2007     Revenue Change
                      ------------ ------- ------------ ------- ------

Revenue:
  Operating revenue   $17,294,027           $15,283,761            13%
  Bulk deliveries to
   customer
   warehouses             552,219             1,228,780           -55%
                      ------------         ------------
Total revenue          17,846,246  100.00%   16,512,541 100.00%     8%

Cost of goods sold     17,287,493            15,906,098             9%
                      ------------         ------------

Gross profit              558,753    3.13%      606,443   3.67%    -8%

Operating expenses:
  Distribution,
   selling and
   administrative         297,607    1.67%      363,367   2.20%   -18%
  Depreciation and
   amortization            23,040    0.13%       22,049   0.13%     4%
  Facility
   consolidations,
   employee severance
   and other                1,384    0.01%          135      -    N/M
                      ------------         ------------

Operating income          236,722    1.33%      220,892   1.34%     7%

Other (income) loss          (992)  -0.01%          376      -    N/M

Interest expense, net      18,726    0.10%        9,889   0.06%    89%
                      ------------         ------------

Income before income
 taxes                    218,988    1.23%      210,627   1.28%     4%

Income taxes               85,136    0.48%       81,131   0.49%     5%
                      ------------         ------------

Net income               $133,852    0.75%     $129,496   0.78%     3%
                      ============         ============


Earnings per share:
  Basic                     $0.83                 $0.69            20%
  Diluted                   $0.82                 $0.68            21%

Weighted average
 common shares
 outstanding:
  Basic                   161,218               188,772
  Diluted                 163,268               191,797

                    AMERISOURCEBERGEN CORPORATION
                          FINANCIAL SUMMARY
                (In thousands, except per share data)
                             (unaudited)


                          Six                  Six
                      Months Ended  % of   Months Ended  % of
                       March 31,    Total   March 31,    Total    %
                          2008     Revenue     2007     Revenue Change
                      ------------ ------- ------------ ------- ------

Revenue:
  Operating revenue   $33,533,454           $30,980,300             8%
  Bulk deliveries to
   customer
   warehouses           1,685,707             2,257,634           -25%
                      ------------         ------------
Total revenue          35,219,161  100.00%   33,237,934 100.00%     6%

Cost of goods sold     34,152,948            32,036,848             7%
                      ------------         ------------

Gross profit            1,066,213    3.03%    1,201,086   3.61%   -11%

Operating expenses:
  Distribution,
   selling and
   administrative         587,547    1.67%      720,328   2.17%   -18%
  Depreciation and
   amortization            45,393    0.13%       44,849   0.13%     1%
  Facility
   consolidations,
   employee severance
   and other                1,561       -         6,158      -    N/M
                      ------------         ------------

Operating income          431,712    1.23%      429,751   1.29%     -

Other (income) loss          (255)      -           442      -    N/M

Interest expense, net      35,150    0.10%       18,032   0.05%    95%
                      ------------         ------------

Income before income
 taxes                    396,817    1.13%      411,277   1.24%    -4%

Income taxes              153,145    0.43%      159,594   0.48%    -4%
                      ------------         ------------

Net income               $243,672    0.69%     $251,683   0.76%    -3%
                      ============         ============


Earnings per share:
  Basic                     $1.49                 $1.32            13%
  Diluted                   $1.48                 $1.30            14%

Weighted average
 common shares
 outstanding:
  Basic                   163,073               190,607
  Diluted                 165,176               193,409

                    AMERISOURCEBERGEN CORPORATION
                CONDENSED CONSOLIDATED BALANCE SHEETS
                            (in thousands)
                             (unaudited)


                  ASSETS
                                             March 31,   September 30,
                                               2008          2007
                                           ------------- -------------
Current assets:
   Cash and cash equivalents                    $591,360      $640,204
   Short-term investment securities
    available-for-sale                                 -       467,419
   Accounts receivable, net                    3,648,094     3,472,358
   Merchandise inventories                     4,528,110     4,101,502
   Prepaid expenses and other                     41,192        32,817
                                           ------------- -------------
      Total current assets                     8,808,756     8,714,300

Property and equipment, net                      529,099       506,984
Other long-term assets                         3,235,121     3,088,780
                                           ------------- -------------

      Total assets                           $12,572,976   $12,310,064
                                           ============= =============


   LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
   Accounts payable                           $7,396,677    $6,988,782
   Current portion of long-term debt               1,616           476
   Other current liabilities                     836,672       867,778
                                           ------------- -------------
      Total current liabilities                8,234,965     7,857,036

Long-term debt, less current portion           1,223,768     1,227,298

Other long-term liabilities                      166,444       126,010

Stockholders' equity                           2,947,799     3,099,720
                                           ------------- -------------

      Total liabilities and stockholders'
       equity                                $12,572,976   $12,310,064
                                           ============= =============

                    AMERISOURCEBERGEN CORPORATION
           CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                            (in thousands)
                             (unaudited)

                                                 Six          Six
                                             Months Ended Months Ended
                                              March 31,    March 31,
                                                 2008         2007
                                             ------------ ------------

Operating Activities:
   Net income                                   $243,672     $251,683
   Adjustments to reconcile net income to
    net cash provided by operating
    activities                                   111,484      106,168
   Changes in operating assets and
    liabilities                                 (262,873)     352,956
                                             ------------ ------------
Net cash provided by operating activities         92,283      710,807
                                             ------------ ------------

Investing Activities:
   Capital expenditures                          (55,105)     (57,397)
   Cost of acquired companies, net of cash
    acquired                                    (162,207)    (144,649)
   Proceeds from sales of property and
    equipment                                        228        4,103
   Net short-term investment activity            467,419     (762,615)
                                             ------------ ------------
Net cash provided by (used in) investing
 activities                                      250,335     (960,558)
                                             ------------ ------------

Financing Activities:
   Net borrowings                                  7,077      107,802
   Deferred financing costs and other               (901)      (2,841)
   Purchases of common stock                    (395,175)    (396,193)
   Exercises of stock options                     22,196       77,290
   Cash dividends on common stock                (24,659)     (19,193)
                                             ------------ ------------
Net cash used in financing activities           (391,462)    (233,135)
                                             ------------ ------------

Decrease in cash and cash equivalents            (48,844)    (482,886)

Cash and cash equivalents at beginning of
 period                                          640,204    1,261,268
                                             ------------ ------------

Cash and cash equivalents at end of period      $591,360     $778,382
                                             ============ ============

                    AMERISOURCEBERGEN CORPORATION
                     SUMMARY SEGMENT INFORMATION
                        (dollars in thousands)
                             (unaudited)


                                       Three Months Ended March 31,
                                    ----------------------------------
Total Revenue                           2008         2007     % Change
----------------------------------- ----------------------------------

Pharmaceutical Distribution         $17,755,838  $16,312,828        9%
Other
   PharMerica Long-Term Care                  -      316,760      N/M
   PMSI                                 105,351      114,600       -8%
                                    ------------ ------------
Total Other                             105,351      431,360      N/M
                                    ------------ ------------

Intersegment eliminations               (14,943)    (231,647)     N/M
                                    ------------ ------------

      Total revenue                 $17,846,246  $16,512,541        8%
                                    ============ ============




                                       Three Months Ended March 31,
                                    ----------------------------------
Operating Income                        2008         2007     % Change
----------------------------------- ----------------------------------

Pharmaceutical Distribution            $237,323     $203,910       16%
Other
   PharMerica Long-Term Care                  -        6,804      N/M
   PMSI                                     783        8,560      -91%
                                    ------------ ------------
Total Other                                 783       15,364      N/M
                                    ------------ ------------

Facility consolidations, employee
 severance and other                     (1,384)        (135)     N/M
Gain on antitrust litigation
 settlements                                  -        1,753      N/M
                                    ------------ ------------

      Operating income                 $236,722     $220,892        7%
                                    ============ ============




Percentages of total revenue:

Pharmaceutical Distribution
      Gross profit                         3.03%        2.98%
      Operating expenses                   1.69%        1.73%
      Operating income                     1.34%        1.25%

Other
      PharMerica Long-Term Care
         Gross profit                       N/A        29.06%
         Operating expenses                 N/A        26.92%
         Operating income                   N/A         2.15%

      PMSI
         Gross profit                     20.37%       22.68%
         Operating expenses               19.63%       15.21%
         Operating income                  0.74%        7.47%

Total Other
      Gross profit                        20.37%       27.37%
      Operating expenses                  19.63%       23.81%
      Operating income                     0.74%        3.56%

AmerisourceBergen Corporation
      Gross profit                         3.13%        3.67%
      Operating expenses                   1.80%        2.33%
      Operating income                     1.33%        1.34%

                    AMERISOURCEBERGEN CORPORATION
                     SUMMARY SEGMENT INFORMATION
                        (dollars in thousands)
                             (unaudited)


                                        Six Months Ended March 31,
                                    ----------------------------------
Total Revenue                           2008         2007     % Change
----------------------------------- ----------------------------------

Pharmaceutical Distribution         $35,035,221  $32,834,805        7%
Other
   PharMerica Long-Term Care                  -      634,715      N/M
   PMSI                                 213,992      232,530       -8%
                                    ------------ ------------
Total Other                             213,992      867,245      N/M
                                    ------------ ------------

Intersegment eliminations               (30,052)    (464,116)     N/M
                                    ------------ ------------

      Total revenue                 $35,219,161  $33,237,934        6%
                                    ============ ============




                                        Six Months Ended March 31,
                                    ----------------------------------
Operating Income                        2008         2007     % Change
----------------------------------- ----------------------------------

Pharmaceutical Distribution            $429,341     $398,043        8%
Other
   PharMerica Long-Term Care                  -       15,887      N/M
   PMSI                                   2,347       18,336      -87%
                                    ------------ ------------
Total Other                               2,347       34,223      N/M
                                    ------------ ------------

Facility consolidations, employee
 severance and other                     (1,561)      (6,158)     N/M
Gain on antitrust litigation
 settlements                              1,585        3,643      -56%
                                    ------------ ------------

      Operating income                 $431,712     $429,751        -
                                    ============ ============




Percentages of total revenue:

Pharmaceutical Distribution
   Gross profit                            2.91%        2.91%
   Operating expenses                      1.69%        1.70%
   Operating income                        1.23%        1.21%

Other
   PharMerica Long-Term Care
      Gross profit                          N/A        29.35%
      Operating expenses                    N/A        26.85%
      Operating income                      N/A         2.50%

   PMSI
      Gross profit                        20.89%       23.47%
      Operating expenses                  19.80%       15.58%
      Operating income                     1.10%        7.89%

Total Other
   Gross profit                           20.89%       27.77%
   Operating expenses                     19.80%       23.83%
   Operating income                        1.10%        3.95%

AmerisourceBergen Corporation
   Gross profit                            3.03%        3.61%
   Operating expenses                      1.80%        2.32%
   Operating income                        1.23%        1.29%

                    AMERISOURCEBERGEN CORPORATION
                          EARNINGS PER SHARE
                (In thousands, except per share data)
                             (unaudited)


Basic earnings per share is computed on the basis of the weighted
 average number of shares of common stock outstanding during the
 periods presented. Diluted earnings per share is computed on the
 basis of the weighted average number of shares of common stock
 outstanding during the periods presented plus the dilutive effect of
 stock options and restricted stock.





                                  Three Months Ended Six Months Ended
                                      March 31,          March 31,
                                    2008      2007     2008     2007
                                  --------- -------- -------- --------

Net income                         $133,852 $129,496 $243,672 $251,683
                                  ========= ======== ======== ========

Weighted average common shares
 outstanding - basic                161,218  188,772  163,073  190,607
Effect of dilutive securities -
 stock options and restricted
 stock                                2,050    3,025    2,103    2,802
                                  --------- -------- -------- --------
Weighted average common shares
 outstanding - diluted              163,268  191,797  165,176  193,409
                                  ========= ======== ======== ========


Earnings per share:
      Basic                           $0.83    $0.69    $1.49    $1.32
      Diluted                         $0.82    $0.68    $1.48    $1.30

CONTACT: AmerisourceBergen Corporation
Michael N. Kilpatric, 610-727-7118
mkilpatric@amerisourcebergen.com

SOURCE: AmerisourceBergen Corporation

Corporate Overview

AmerisourceBergen is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. With services ranging from drug distribution and niche premium logistics to reimbursement and pharmaceutical consulting services, AmerisourceBergen delivers innovative programs and solutions across the pharmaceutical supply channel..

Learn More